Why the study?
Much data informing sex differences in AF comes from Western cohorts, leaving these differences poorly characterized in the Indian subcontinent.
Do 12-month MACE and bleeding outcomes differ by sex in Indian patients with atrial fibrillation?
Cohort
Yes
Do 12-month MACE and bleeding outcomes differ by sex in Indian patients with atrial fibrillation?
Absolute Event Rate: 30.2% vs 29.4%
p-value: p=0.685
In a large Indian atrial fibrillation registry, 12-month MACE rates were similar between sexes, but males had higher bleeding rates and differing baseline comorbidities compared to females.
Background Much data informing sex differences in atrial fibrillation (AF) comes from Western cohorts. In this analysis, we describe sex differences in Kerala, India, using the Kerala‐AF registry—the largest AF registry from the Indian subcontinent. Methods Patients aged ≥18 years were recruited from 53 hospitals across Kerala. Patients were compared for demographics, treatments, and 12‐month outcomes, including major adverse cardiovascular events (MACE) and bleeding. Results Male patients were more likely to have a smoking and/or alcohol history and had more ischaemic heart disease (46.2% vs. 25.5%; p < 0.001). Female patients had more valvular AF (35.1% vs. 18.0%; p < 0.001), and more use of calcium‐channel blockers (23.3% vs. 16.5%; p < 0.001) or digoxin (39.6% vs. 28.5%; p < 0.001). Almost one in four patients were not anticoagulated despite raised CHA 2 DS 2 ‐VASc scores. 12‐month MACE outcomes did not differ by sex (male: 30.2% vs. female: 29.4%; p = 0.685), though bleeding events were more common in male patients (2.4% vs. 1.3%; p = −0.038), driven by minor bleeding (1.2% vs. 0.5%). Conclusion In this large AF cohort from India, male patients had a higher prevalence of ischaemic heart disease, smoking, and alcohol use, while female patients had a higher prevalence of valvular heart disease. MACE did not differ by sex, though bleeding was more common in males. Almost a quarter of patients were not anticoagulated despite raised thromboembolic risk.
No takes yet. Share an insight, caveat, or question.
Calvert et al. (2024) conducted a cohort in Atrial fibrillation. Male sex vs. Female sex was evaluated on 12-month major adverse cardiovascular events (MACE) (p=0.685).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: